4D Molecular Therapeutics (FDMT) Asset Utilization Ratio (2021 - 2026)

4D Molecular Therapeutics (FDMT) has reported Asset Utilization Ratio for 6 consecutive years, with 0.16 the latest figure, recorded in Q1 2026.

• In Q1 2026, Asset Utilization Ratio rose 382316.02% year-over-year to 0.16; the TTM figure through Mar 2026 stood at 0.16 (up 382316.02% YoY), while the FY2025 annual figure was 0.15, up 183849.42% from the prior year.
• Asset Utilization Ratio fell to 0.16 in Q1 2026 per FDMT's latest filing, from 0.17 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 0.17 in Q4 2025 and bottomed at 0.0 in Q3 2024.
• Historically, Asset Utilization Ratio has averaged 0.04 across 5 years, with a median of 0.01 in 2022.
• Annual changes were most pronounced in 2024 — Asset Utilization Ratio tumbled 99.95% — and 2026, when it soared 382316.02%.
• 4D Molecular Therapeutics' Asset Utilization Ratio stood at 0.01 in 2022, then jumped by 411.85% to 0.06 in 2023, then plunged by 99.89% to 0.0 in 2024, then soared by 270576.98% to 0.17 in 2025, then fell by 4.97% to 0.16 in 2026.
• Business Quant data shows FDMT's Asset Utilization Ratio at 0.16 in Q1 2026, 0.17 in Q4 2025, and 0.0 in Q3 2025.